Related references
Note: Only part of the references are listed.PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer
Taisuke Yagi et al.
ANNALS OF SURGERY (2019)
Prognostic Role of Tumor-Infiltrating Lymphocytes in Esophagus Cancer: a Meta-Analysis
Xiao Zheng et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
LAG-3 in Non-Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival
Sigurd M. Hald et al.
CLINICAL LUNG CANCER (2018)
Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy
Florent Amatore et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma
Toshihiko Doi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
TIM-3, a promising target for cancer immunotherapy
Yayi He et al.
ONCOTARGETS AND THERAPY (2018)
Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma
Yu Zhang et al.
JOURNAL OF CANCER (2018)
New checkpoints in cancer immunotherapy
Ling Ni et al.
IMMUNOLOGICAL REVIEWS (2017)
Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer
Thomas W. Rice et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
Yayi He et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo et al.
LANCET ONCOLOGY (2017)
Integrated genomic characterization of oesophageal carcinoma
Jihun Kim et al.
NATURE (2017)
Induction of anti-aging gene klotho with a small chemical compound that demethylates CpG Islands
Dongju Jung et al.
ONCOTARGET (2017)
Prognosis and Progression of ESCC Patients with Perineural Invasion
Guanghui Xu et al.
SCIENTIFIC REPORTS (2017)
Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma
Dongxian Jiang et al.
SCIENTIFIC REPORTS (2017)
Combination immunotherapy: a road map
Patrick A. Ott et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
Siwen Hu-Lieskovan et al.
CANCER JOURNAL (2017)
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy
Adam C. Palmer et al.
CELL (2017)
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely
Daphne Day et al.
CLINICAL CANCER RESEARCH (2017)
Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma
Satoshi Tsutsumi et al.
CANCER SCIENCE (2017)
State of the art in anti-cancer mAbs
S. M. Chiavenna et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer
Hirofumi Matsumoto et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
Hye Ryun Kim et al.
SCIENTIFIC REPORTS (2016)
OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs
Jordan Anaya
PEERJ COMPUTER SCIENCE (2016)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Vishwanath Sathyanarayanan et al.
MOLECULAR ONCOLOGY (2015)
Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Ana C. Anderson
CANCER IMMUNOLOGY RESEARCH (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer
Jing Jiang et al.
PLOS ONE (2013)
Ectopic Expression of TIM-3 in Lung Cancers A Potential Independent Prognostic Factor for Patients With NSCLC
Xuewei Zhuang et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy
Justin K. Smit et al.
AMERICAN JOURNAL OF SURGERY (2010)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines
M Lopez et al.
IMMUNOBIOLOGY (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma
Y Doki et al.
WORLD JOURNAL OF SURGERY (2005)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Enhancement of CD8+ T cell responses by ICOS/B7h costimulation
JJ Wallin et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
